The Role of Screening and Treatment in National Progress Toward Hepatitis C Elimination - Georgia, 2015-2016
| Autor: | Lia Gvinjilia, Maia Alkhazashvili, Lali Sharvadze, Muazzam Nasrullah, David Metreveli, Shaun Shadaker, Amiran Gamkrelidze, Tengiz Tsertsvadze, David Sergeenko, Maia Butsashvili, John W. Ward, Juliette Morgan, Francisco Averhoff |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Male medicine.medical_specialty Health (social science) Adolescent Epidemiology Health Toxicology and Mutagenesis Hepatitis C virus Psychological intervention medicine.disease_cause Antiviral Agents Georgia (Republic) Virus Young Adult 03 medical and health sciences 0302 clinical medicine Health Information Management Internal medicine Prevalence medicine Humans Mass Screening Full Report 030212 general & internal medicine Disease Eradication Young adult Mass screening Aged business.industry virus diseases General Medicine Hepatitis C Middle Aged medicine.disease Virology United States digestive system diseases Virologic response Female 030211 gastroenterology & hepatology Erratum business Program Evaluation |
| Zdroj: | MMWR. Morbidity and Mortality Weekly Report |
| ISSN: | 1545-861X 0149-2195 |
| DOI: | 10.15585/mmwr.mm6629a2 |
| Popis: | Georgia, a country in the Caucasus region of Eurasia, has a high prevalence of hepatitis C virus (HCV) infection. In April 2015, with technical assistance from CDC, Georgia embarked on the world's first program to eliminate hepatitis C, defined as a 90% reduction in HCV prevalence by 2020 (1,2). The country committed to identifying infected persons and linking them to care and curative antiviral therapy, which was provided free of charge through a partnership with Gilead Sciences (1,2). From April 2015 through December 2016, a total of 27,595 persons initiated treatment for HCV infection, among whom 19,778 (71.7%) completed treatment. Among 6,366 persons tested for HCV RNA ≥12 weeks after completing treatment, 5,356 (84.1%) had no detectable virus in their blood, indicative of a sustained virologic response (SVR) and cure of HCV infection. The number of persons initiating treatment peaked in September 2016 at 4,595 and declined during October-December. Broader implementation of interventions that increase access to HCV testing, care, and treatment for persons living with HCV are needed for Georgia to reach national targets for the elimination of HCV. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|